
Nulla consequat massa quis enim.
Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque

Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur

Project ALS researcher Dr. Tom Maniatis, Columbia University, gives an update on ALS research.

Project ALS funds critical drug testing at Columbia University and Massachusetts General Hospital/Harvard Medical School. The Project ALS Pre-Clinical Core at Columbia is currently testing

The world is closer to understanding the causes of ALS. However, the most important power source in the fight to find medicine these days is…patients

Project ALS funds a four-lab consortium working to understand why the motor neurons controlling the eye movement—ocular motor neurons, or OMNs—remain functional in ALS, while

Project ALS is pleased to share that the FDA has approved the drug edaravone – the first approved ALS treatment in over 20 years. Edaravone,

Results of four recently published Project ALS studies shed new light on how ALS happens, and strategies for slowing the disease. Project ALS teams led